SEEMA NAGPAL
🇦🇺Australia
- Country
- 🇦🇺Australia
- Ownership
- -
- Employees
- -
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
Phase 1
Completed
- Conditions
- Astrocytoma of BrainGliosarcomaGlioblastomaRecurrent Glioblastoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Seema Nagpal
- Target Recruit Count
- 12
- Registration Number
- NCT03020602
- Locations
- 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States
News
No news found